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The antibiotic classes that are recommended for tularaemia treatment are the
aminoglycosides, the fluoroquinolones and the tetracyclines. However, cure rates vary
between 60 and 100% depending on the antibiotic used, the time to appropriate
antibiotic therapy setup and its duration, and the presence of complications, such as
lymph node suppuration. Thus, antibiotic susceptibility testing (AST) of F. tularensis
strains remains of primary importance for detection of the emergence of antibiotic
resistances to first-line drugs, and to test new therapeutic alternatives. However, the
AST methods reported in the literature were poorly standardized between studies and
AST data have not been previously evaluated in a comprehensive and comparative
way. The aim of the present review was to summarize experimental data on antibiotic
susceptibilities of F. tularensis obtained in acellular media, cell models and animal
models since the introduction of fluoroquinolones in the treatment of tularaemia in 1989.
We compiled MIC data of 33 antibiotics (including aminoglycosides, fluoroquinolones,
tetracyclines, macrolides, β-lactams, chloramphenicol, rifampicin, and linezolid) against
900 F. tularensis strains (504 human strains), including 107 subsp. tularensis (type A),
789 subsp. holarctica (type B) and four subsp. mediasiatica strains, using various AST
methods. Specific culture media were identified or confirmed as unsuitable for AST of
F. tularensis. Overall, MICs were the lowest for ciprofloxacin (≤ 0.002–0.125mg/L) and
levofloxacin, and ranged from≤ 0.016 to 2 mg/L for gentamicin, and 0.064 to 4 mg/L for
doxycycline. No resistant strain to any of these antibiotics was reported. Fluoroquinolones
also exhibited a bactericidal activity against intracellular F. tularensis and lower relapse
rates in animal models when compared with the bacteriostatic compound doxycycline.
As expected, lower MIC values were found for macrolides against type A and biovar I
type B strains, compared to biovar II type B strains. The macrolides were more effective
against F. tularensis grown in phagocytic cells than in acellular media.
Keywords: Francisella tularensis, antimicrobial susceptibility, MIC, MBC, intracellular, animal model, tularaemia,
antibiotic therapy
Caspar and Maurin Francisella tularensis Susceptibility to Antibiotics
SEARCH STRATEGY AND SELECTION
CRITERIA
Data on antibiotic susceptibility testing (AST) of Francisella
tularensis, both in vitro and in animal models, were collected
from the English and French literature in the PubMed database,
since the introduction of fluoroquinolones in the treatment of
tularaemia in 1989 until December 2016. They were extracted
using the key words “tularemia” and “Francisella” in order to
achieve a broad screening of the entire body of literature on
the subject since 1989. Only studies evaluating more than five F.
tularensis strains were selected for analysis.
FRANCISELLA TULARENSIS AND
TULAREMIA
F. tularensis, the etiological agent of tularaemia, is a Tier 1
biological threat agent according to the classification of the
Centers for Disease Control and Prevention (Dennis et al., 2001).
It was first isolated from ground squirrels in 1911 in Tulare
County, California (USA), and from a human tularaemia case
in 1914 in Ohio (USA) (Mccoy and Chapin, 1912; Wherry and
Lamb, 1914). The name “Francisella tularensis” was coined in
1959 to honor Dr. Edward Francis, who greatly contributed to
improve the knowledge on human tularaemia (Francis et al.,
1922; Francis, 1928; Rockwood, 1983). Francisella tularensis is
currently divided into three subspecies: subsp. tularensis (type A
strains), mainly found in North America; subsp. holarctica (type
B strains) found throughout the northern hemisphere; and subsp.
mediasiatica found in Central Asia (Olsufiev et al., 1959; Jellison
and Owen, 1961; Olsufjev, 1970; Jellison, 1974; Olsufjev and
Meshcheryakova, 1983). Debate continues on whether Francisella
novicida is a fourth subspecies of F. tularensis or a separate
species, but we agree with Johansson et al. in keeping F. novicida
in a separate species because of its aquatic reservoir and very
low virulence in humans (Busse et al., 2010; Huber et al.,
2010; Johansson et al., 2010). Type B strains are also classically
differentiated into three biovars (Kudelina and Olsufiev, 1980;
Olsufjev and Meshcheryakova, 1982, 1983): biovar I (naturally
susceptible to erythromycin) is found in Western Europe and
North America; biovar II (naturally resistant to erythromycin)
is found in Eastern Europe and Asia; and biovar japonica
(susceptible to erythromycin but fermenting glycerol) is mainly
found in Japan, although it has recently been described in China
and Turkey (Kiliç et al., 2013; Wang et al., 2014). Biovar II
strains are found in the Eastern part of Europe (Czech Republic,
Finland, Georgia, Russia, Slovakia, Ukraine, Austria, Hungary,
and Romania) (Vogler et al., 2009; Svensson et al., 2009b;
Chanturia et al., 2011; Gyuranecz et al., 2012) and in Asia and
both biovar I and II strains coexist in Germany, Switzerland and
Scandinavia (Muller et al., 2013; Origgi et al., 2014; Maurin and
Gyuranecz, 2016).
Although the F. tularensis genome displays very low
variability, four distinct clades have been identified by pulse-field
gel electrophoresis (PFGE) within type A strains in the United
States (A.Ia, A.Ib, A.IIa, and A.IIb) with the A.Ib clade being
associated with a 24% mortality rate in humans (Kugeler et al.,
2009). Type B strains have also been divided into several clades
by whole genome sequencing. The four main clades include
clade B.4 corresponding to North American strains, clade B.6 to
biovar IWestern European strains, clade B.12 to biovar II Eastern
European strains, and clade B16 to strains belonging to biovar
japonica (Fujita et al., 2008; Vogler et al., 2009; Kilic et al., 2015;
Karlsson et al., 2016).
F. tularensis is a Gram-negative, facultative intracellular
coccobacillus (Broman et al., 2011). It is strictly aerobic, non-
motile, non-toxigenic, and non-spore-forming. It is a fastidious
bacterium that may be grown in cysteine-enriched media,
under 5% CO2 atmosphere. The main virulence factor of
F. tularensis corresponds to its ability to multiply within
eukaryotic cells, especially in the cytosol of macrophages
(Clemens and Horwitz, 2007). Virulence is associated with the
presence of a duplicated pathogenicity island in the bacterial
genome, encoding a type VI-like secretion system (Nano and
Schmerk, 2007). However, the high variations in virulence
observed among F. tularensis genotypes remain currently
unexplained.
Human tularaemia is a zoonotic disease usually occurring
as sporadic cases or small familial outbreaks (Tärnvik and
Berglund, 2003; Bicakci and Parlak, 2008). However, a number
of tularaemia outbreaks have been reported, including in the last
two decades (Helvaci et al., 2000; Cerný, 2001; Feldman et al.,
2001; Pérez-Castrillón et al., 2001; Reintjes et al., 2002; Christova
et al., 2004; Payne et al., 2005; Celebi et al., 2006; Kantardjiev
et al., 2006; Siret et al., 2006; Petersen et al., 2008; Akalın et al.,
2009; Barut and Cetin, 2009; Svensson et al., 2009a; Hauri et al.,
2010; Mailles et al., 2010; Larssen et al., 2011, 2014; Wang et al.,
2011; Karlsson et al., 2013; Johansson et al., 2014; Mengeloglu
et al., 2014). Humans may be infected with F. tularensis through
direct contact with infected animals (manipulation of live or
dead infected animals, animal bites or scratches), consumption
of contaminated food or water, exposure to contaminated
environments or through arthropod bites (Keim et al., 2007).
F. tularensis can infect a large number of animal species, but
lagomorphs and small rodents are considered key hosts for this
pathogen (Gyuranecz et al., 2011; Maurin and Gyuranecz, 2016).
This bacterium may also persist in water and soil environments
for several months, which might be related to an ability to
multiply in protozoa, such as amoebae (Abd et al., 2003; Keim
et al., 2007; El-Etr et al., 2009; Broman et al., 2011). A terrestrial
and an aquatic lifecycle have been described for this bacterium
(Maurin and Gyuranecz, 2016). Arthropods, such as ticks and
mosquitoes may be contaminated by F. tularensis from the
animal or environmental reservoirs (Sjostedt, 2007; Maurin and
Gyuranecz, 2016). Large tularaemia outbreaks have occurred, for
whichmultiple sources of contamination and several F. tularensis
clones were identified (Akalın et al., 2009; Barut and Cetin, 2009;
Celebi et al., 2006; Cerný, 2001; Christova et al., 2004; Feldman
et al., 2001; Hauri et al., 2010; Helvaci et al., 2000; Johansson
et al., 2014; Kantardjiev et al., 2006; Karlsson et al., 2013;
Larssen et al., 2011, 2014; Mailles et al., 2010; Mengeloglu et al.,
2014; Payne et al., 2005; Pérez-Castrillón et al., 2001; Petersen
et al., 2008; Reintjes et al., 2002; Siret et al., 2006; Svensson
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et al., 2009a; Wang et al., 2011). Symptoms vary according to
the infection route and classically correspond to six different
clinical forms: ulceroglandular, glandular, oropharyngeal,
oculoglandular, pneumonic and typhoidal (Tarnvik, 2007).
Ulceroglandular and glandular forms are consecutive to skin
inoculation of bacteria (e.g., through an arthropod bite or
contact with infected animals). A regional lymphadenopathy
develops with (ulceroglandular form) or without (glandular
form) a skin ulcer at the inoculation site. When contamination
occurs through the ocular conjunctiva, painful conjunctivitis
with regional lymphadenopathy develops, which corresponds
to oculoglandular tularaemia. The oropharyngeal form is
characterized by pharyngitis with regional lymphadenopathy,
usually occurring after consumption of contaminated meat
or water. Pneumonic tularaemia results from airborne
contamination or hematogenous spread of bacteria to the
lungs and is characterized by unspecific symptoms, such as
cough, fever, dyspnea and occasionally a mediastinal or hilar
lymphadenopathy. The typhoidal form corresponds to systemic
disease with neurological symptoms mimicking typhoid,
often with F. tularensis bacteraemia, but without detection of
any portal of entry of bacteria (especially no skin ulcer) and
without symptoms of localized infection (especially no regional
lymphadenopathy) (Tärnvik and Chu, 2007). Complications may
occur, such as skin eruptions, abscess formation, lymph node
suppuration with occasionally skin fistulisation, and secondary
infectious locations due to hematogenous spread of bacteria
(Tärnvik and Chu, 2007; Meric et al., 2008; Maurin et al., 2011;
Erdem et al., 2014). Diagnosis is usually based on compatible
clinical and epidemiological features, and positive serological
tests. PCR is useful to detect F. tularensis DNA in various clinical
samples, especially before specific antibodies can be detected
(Tarnvik, 2007). Isolation of a F. tularensis strain from blood or
tissue samples is obtained in <20% of patients, which makes
antibiotic susceptibility testing (AST) of F. tularensis strains rare
(Maurin et al., 2011).
The 2007 WHO guidelines for treatment of tularaemia are
based on the 2001 consensus recommendations from Dennis
et al. (2001). According to these publications, tularaemia
treatment is mainly based on three antibiotic classes: the
aminoglycosides, the fluoroquinolones and the tetracyclines,
although many other antibiotic classes have been tested against
F. tularensis in vitro. Here we have compiled all available
experimental data on the evaluation of the activity of antibiotics
against F. tularensis in vitro, in acellular and cell models, and in
vivo in animal models to provide useful information for clinical
microbiologists and physicians.
ANTIBIOTIC SUSCEPTIBILITY TESTING OF
F. TULARENSIS
Antibiotic susceptibility testing (AST) of F. tularensis strains is
usually not performed on a routine basis because: (1) isolation
of the strain involved is only obtained in a few tularaemic
patients (Maurin et al., 2011); (2) this procedure is at risk for the
laboratory personnel handling cultures of this highly infectious
pathogen and requires biosafety level 3 (BSL3) facilities (Tärnvik
and Chu, 2007); (3) acquired resistance to antibiotics has never
been reported so far in clinical strains of F. tularensis (Tarnvik,
2007) and (4) in vitro data may not be predictive of treatment
failure in tularaemia patients. However, reference laboratories
have reported AST surveys for collections of human and animal
strains of F. tularensis (Scheel et al., 1993; Ikäheimo et al., 2000;
Johansson et al., 2000, 2002; García del Blanco et al., 2004;
Tomaso et al., 2005; Urich and Petersen, 2008; Valade et al., 2008;
Velinov et al., 2011; Yes¸ilyurt et al., 2011; Georgi et al., 2012;
Hotta et al., 2013; Kiliç et al., 2013; Kreizinger et al., 2013; Origgi
et al., 2014).
For this review, we collected F. tularensis AST results from
all studies of more than five tularaemia cases, published in the
literature since 1989. We obtained data from 898 F. tularensis
strains isolated from humans (510 strains), animals (200 strains),
arthropods (four strains), natural water samples (39 strains) and
unknown sources (147). They included 107 type A, 789 type B
and four F. tularensis subsp. mediasiatica strains (Table 1 and
Table S1) (Scheel et al., 1993; Ikäheimo et al., 2000; Johansson
et al., 2000, 2002; García del Blanco et al., 2004; Tomaso et al.,
2005; Urich and Petersen, 2008; Valade et al., 2008; Velinov et al.,
2011; Yes¸ilyurt et al., 2011; Georgi et al., 2012; Hotta et al., 2013;
Kiliç et al., 2013; Kreizinger et al., 2013; Origgi et al., 2014). AST
results were available for 33 antibiotics, although only some
of them were tested in all studies (Tables 1–5 and Table S1).
These antibiotics included four aminoglycoside compounds
(gentamicin, streptomycin, amikacin and tobramycin), nine
fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin,
ofloxacin, norfloxacin, grepafloxacin, sparfloxacin, trovafloxacin
and gatifloxacin), three tetracyclines (tetracycline, doxycycline
and tigecycline), four macrolides (erythromycin, azithromycin,
roxithromycin and clarithromycin), one ketolide (telithromycin),
nine β-lactams (ampicillin, amoxicillin + clavulanic acid,
ceftazidime, piperacillin + tazobactam, ceftriaxone, cefepime,
imipenem, meropenem and aztreonam), chloramphenicol,
rifampicin, and linezolid.
MICs: Methods and Results
According to the Clinical and Laboratory Standards Institute
(CLSI) and WHO guidelines, AST of F. tularensis strains
should be performed using cation-adjusted Mueller-Hinton
broth enriched with 2% defined growth supplement, such as
Polyvitex R© (referred to here as enriched caMHB), in order
to fulfill the cystein growth requirement of this bacterium
(Tarnvik, 2007; CLSI. M45-A2, 2010). Adjustment of pH
to 7.1 ± 0.1 is mandatory after addition of 2% growth
supplement because it significantly reduces the pH of caMHB
medium. The bacterial inoculum must be calibrated at 5
105 CFU/mL of final concentration. Culture media should
be incubated for 48 h in ambient air, but incubation in 5%
CO2-enriched atmosphere may be needed for some strains,
although it can lead to acidification of the culture medium
and therefore overestimation of aminoglycoside and macrolide
MICs, or underestimation of tetracyclines MICs (CLSI. M45-A2,
2010).
In the past three decades, three different methods for F.
tularensis AST were most frequently reported in the literature:
antibiotic agar dilution, broth microdilution and E-test strips.
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TABLE 2 | MIC and MIC90 ranges of aminoglycosides, tetracyclines and
fluoroquinolones against F. tularensis.
Antibiotics MIC range MIC90 range CLSI breakpoint for
(mg/L) (mg/L) susceptibility (mg/L)
Gentamicin ≤0.016–2 0.064–1 ≤ 4
Streptomycin ≤0.064–8 0.25–6 ≤ 8
Tetracycline ≤0.094–2 ≤ 0.25- 1 ≤ 4
Doxycycline 0.064–4 0.25–2 ≤ 4
Ciprofloxacin ≤0.002–0.125 ≤ 0.016–0.064 ≤ 0.5
Levofloxacin ≤0.004–0.125 0.012–0.125 ≤ 0.5
Chloramphenicol ≤0.023–4 ≤ 0.25–2 ≤ 8
Data are summarised from all studies selected for this review.
These techniques were poorly standardized between studies,
including after CLSI guidelines were available (CLSI. M45-A2,
2010). Most particularly, growth media, incubation conditions
(atmosphere and duration) and bacterial inocula used for F.
tularensis AST greatly varied between studies. Therefore, the
results obtained in these different studies should be compared
with caution.
As for the broth microdilution method, a number of authors
used Mueller-Hinton II broth supplemented with glucose, Ca2+
and Mg2+ ions, and ferric pyrophosphate (a medium referred
to as modified MHII) in spite of the recommended enriched
caMHBmedium (Baker et al., 1985; García del Blanco et al., 2004;
Origgi et al., 2014). The use of MHII resulted in overestimation
of the MICs of aminoglycosides and tetracyclines compared
to caMHB (Table S1). The use of MHII for F. tularensis
AST should be discouraged to avoid erroneous classification of
some strains as resistant to aminoglycosides and/or tetracyclines
using the CLSI breakpoints for susceptibility (concentration
value threshold used for the categorization of a bacterial
strain as susceptible, intermediately susceptible or resistant to
an antibiotic). To date, antibiotic resistance reported in the
literature for natural strains of F. tularensis have never been
formally characterized by a reference laboratory. In the following
paragraphs, the term resistant is applied to strain whose MICs
are not classified as susceptible according to CLSI breakpoints
for susceptibility, even though the mechanism of resistance has
not been characterized. The MHII medium may also affect the
activity of fluoroquinolones since ciprofloxacin MICs up to 0.25
mg/L were reported with this medium (Maurin et al., 2000;
García del Blanco et al., 2004), while MICs for this antibiotic
range from ≤ 0.002 to 0.125 mg/L (MIC90, ≤ 0.016–0.047 mg/L)
for all other studies reported (Table 1 and Table S1).
Several agar media were used for MIC determination
using the E-test strip technique (Tables 1 and Table S1).
MIC ranges observed with these different solid media were
similar to each other and to those obtained with the broth
microdilution method using enriched caMHB. No strain was
classified as resistant to any of the drugs used for tularaemia
treatment and for which CLSI breakpoints have been defined
(i.e., gentamicin, streptomycin, ciprofloxacin, levofloxacin,
tetracycline, doxycycline and chloramphenicol). Thus, the E-test
strip methodology appears to be a convenient alternative for TA
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TABLE 5 | MICs of beta-lactams against F. tularensis.
Reference Origin Nb of strains
Type/biovar
MIC range (mg/L)
AMP AMC PIP/TAZ CAZ COX FEP IMI MER AZT
BROTH MICRODILUTION
Georgi et al., 2012 Europe 69 B 64->64 >32 16->16
E-TEST
Hotta et al., 2013 Japan 34 B 0.047->256 0.047->32 0.094->32 0.75->256
Yes¸ilyurt et al., 2011 Turkey 39 B biovar II >256 >256 >256 >256 >256 >256 >32
Tomaso et al., 2005 Austria 50 B biovar II >256 >256 >256 >32 >32 0.5->32 1.5->32 >256
Ikäheimo et al., 2000 Finland 38 B >256 >256 >32 >32 >32
Velinov et al., 2011 Bulgaria 21 B biovar II >256 2-4
AGAR DILUTION
Scheel et al., 1993 Scandinavia 20 B >32 >32 >32 >32
*if available, MIC90 value corresponded every time to the highest value of MIC range. AMP, Ampicillin; AMC, Amoxicillin/Clavulanate; PIP/TAZ, Piperacillin/tazobactam; CAZ, Ceftazidime;
COX, Ceftriaxone; FEP, Cefepime; IMI, Imipenem; MER, Meropenem; AZT, Aztreonam.
antibiotic susceptibility categorisation of F. tularensis strains
compared to the more time-consuming and fastidious broth
microdilution method. Moreover, this method is less risky for
laboratory personnel because it does not require handling large
volumes of liquid suspensions of F. tularensis. However, no
study has compared AST results using MIC strips to those of
the microdilution reference method using enriched caMHB.
Standardization of agar media for F. tularensis AST would be
beneficial for comparison of studies conducted in different
laboratories.
A few studies have compared F. tularensis antibiotic
susceptibilities when using the agar dilution technique with
different solid media (Table 1 and Table S1). Blood cysteine
agar should be avoided since it identified resistant strains of
F. tularensis for gentamicin or streptomycin, which was never
confirmed by characterizing the resistance mechanisms involved.
For the Thayer Martin agar and enriched Mueller-Hinton agar,
results were concordant with those of the broth microdilution
and MIC strip assays. One study compared MIC results using
the agar dilution method, the MIC strip method or the broth
microdilution reference method. Unfortunately, results obtained
with the referencemethodwere not reproducible. The correlation
of results obtained with either the agar dilution orMIC strip tests,
using enriched Mueller Hinton agar, were 87% for doxycycline,
94% for ciprofloxacin, but only 42% for gentamicin. The agar
dilution method poorly correlated with the broth microdilution
method, with only 72% correlation for doxycycline, 68% for
ciprofloxacin and 51% for gentamicin.
According to our previous comments on MIC methods, we
excluded MIC values obtained with the broth microdilution
method using modified MHII broth and those determined by
the agar dilution method using blood cystein agar plates (Table
S1) MICs obtained with all other methods were recorded,
although analyzed cautiously because of poor methodological
standardization, as previously mentioned. The remaining 812
F. tularensis strains were categorized as susceptible to first-line
antibiotics for tularaemia, including the aminoglycosides, the
fluoroquinolones and the tetracyclines. MIC ranges and CLSI
breakpoints for these antibiotics are shown in Table 2.
Aminoglycosides, Fluoroquinolones, and Doxycycline
Altogether, among antibiotic classes recommended for
first-line treatment of tularaemia, ciprofloxacin displayed
the lowest ranges for MICs (≤ 0.002–0.125mg/L) and MICs90
(≤0.016–0.064mg/L) between studies. Gentamicin MICs ranged
from ≤ 0.016 to 2mg/L, and MICs90 from 0.064 to 1mg/L. The
MIC and MIC90 ranges for doxycycline were 0.064–4mg/L and
0.25–2mg/L, respectively (Table 1). Only slight differences in
susceptibility to these antibiotics were observed between type A
and type B strains of F. tularensis, or between various biovars or
clades within type A and type B strains.
Among fluoroquinolones, ciprofloxacin and levofloxacin
were the most active compounds in vitro (Table 1). All
strains tested displayed MIC levels to these antibiotics at
least 4-fold less than the CLSI breakpoint for susceptibility
(Table 2). Moxifloxacin, norfloxacin, gatifloxacin, grepafloxacin,
trovafloxacin and sparfloxacin were also effective against F.
tularensis in vitro (Table 3), but the three latter antibiotics have
been withdrawn from the market because of potential severe side
effects.
As for the aminoglycosides, tobramycin and amikacin were
evaluated in three studies, only against type B strains (Ikäheimo
et al., 2000; Tomaso et al., 2005; Yes¸ilyurt et al., 2011).
Tobramycin displayed MIC values (0.125–3mg/L) close to those
of gentamicin and streptomycin. Interestingly, Enderlin et al.,
reported in 1994 a cure rate with this antibiotic of only 50% but
for a limited number of patients (3/6 patients) (Enderlin et al.,
1994). Conversely, amikacin was less active in vitro, with MICs
up to 16mg/L (Table 3; Tomaso et al., 2005).
Thus all strains were confirmed as susceptible to the
first-line antibiotics recommended for tularemia treatment,
with ciprofloxacin and levofloxacin showing the lowest MICs
in vitro.
Macrolides
Erythromycin MICs are much higher for biovar II F. tularensis
subsp. holarctica strains, than for biovar I strains of the same
subspecies and for F. tularensis subsp. tularensis strains. Kudelina
et al first described erythromycin-resistant strains of F. tularensis
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as those able to grow on media containing up to 6400mg/L
of this antibiotic, while susceptible strains could be killed by
25mg/L of this antibiotic (Kudelina and Olsufiev, 1980). In the
literature, type B biovar II strains, which currently correspond
to East European strains belonging to the B12 subclade, were all
resistant to erythromycin with MIC > 256mg/L using the E-test
strip method (Table 4; Karlsson et al., 2016). Only Tomaso et al.
reported one biovar II strain with an erythromycin MIC of only
4mg/L, but this result can be questioned according to current
literature (Tomaso et al., 2005). Using the broth microdilution
method, all type B biovar II strains had erythromycin MICs
of ≥ 32mg/L (Table 1). In contrast, all type B biovar I
strains displayed erythromycin MICs ≤ 8mg/L using the broth
microdilution method and ≤ 1mg/L using MIC strips. Among
erythromycin-susceptible F. tularensis strains, subtle differences
in erythromycin MICs could be found in the literature between
the US strains belonging either to type B biovar I (MIC range,
0.125–2mg/L; MIC90 range, 0.5–1mg/L) or to type A (MIC
range, 0.125–1mg/L), and the West European type B biovar I
strains (MIC range, 1–8mg/L; MIC90, 4mg/L). This difference
might be correlated with the B6 clade displaying higher MIC
levels, or to methodological differences, such as incubation of
media in ambient air vs. under 5% CO2 atmosphere, the latter
reducing the activity of the macrolides. The Japanese type B
strains, including those formally identified as belonging to biovar
japonica, displayed erythromycin MICs ranging from 0.094 to
1.5mg/L.
According to the above data, a breakpoint for the biovar
II definition might be set at erythromycin MIC ≥ 32mg/L, in
agreement with Kudelina’s above-mentioned study (Kudelina and
Olsufiev, 1980). Moreover, erythromycin resistance in type B
biovar II strains has recently been correlated with the presence
of a single mutation A2059C in the three copies of the rrl
gene, encoding the 23S rRNA (Karlsson et al., 2016). Thus,
determination of the rrl gene sequence provides a confirmatory
identification of biovar II subtype.
AzithromycinMICs against F. tularensiswere also determined
in three studies, with the same dichotomy between biovar I
and biovar II of type B strains. MIC ranges were similar to
those observed for erythromycin (Table 4). Biovar II strains
displayed azithromycin MICs > 256mg/L, whereas MIC ranges
were 0.064–2mg/L for 16 type B and 0.125–2mg/L for eight type
A strains from the USA (Ikäheimo et al., 2000; Johansson et al.,
2002; Yes¸ilyurt et al., 2011). Telithromycin, a ketolide compound,
displayed MICs ranging from 0.125 to 0.25mg/L with the agar
dilution method against type B biovar I strains (Valade et al.,
2008).
Thus, low MIC values are observed for macrolides and one
ketolide against biovar I strains. No susceptibility breakpoints
are currently defined by the CLSI for these antibiotics against
F. tularensis, although they may represent useful therapeutic
alternatives for infection related to biovar I strains, especially
if first-line antibiotics are contraindicated. Further experimental
data in animal models are needed for the in vivo evaluation of
the activity of these compounds against F. tularensis. In contrast,
the macrolides and ketolides are ineffective against biovar II
strains.
Beta-Lactams
Many β-lactams have been tested in vitro against F. tularensis,
although they are considered unreliable for treatment of
tularaemia (Cross and Jacobs, 1993; Cross et al., 1995; Tarnvik,
2007; Maurin et al., 2011). In the literature, all the F. tularensis
strains tested were resistant to penicillin A, ticarcillin and
piperacillin, whether or not associated with a β-lactamase
inhibitor, with MICs ≥ 64mg/L (Table 5). In contrast, the
cephalosporins, monobactams and carbapenems displayed larger
MIC ranges. Although most F. tularensis strains displayed MICs
higher than 32mg/L to these β-lactams, a few strains displayed
MICs lower than 1mg/L (Table 5). In a study from Hotta
et al., 30–60% of 36 Japanese strains displayed MICs lower
than 1mg/L for cefotaxime, ceftriaxone, cefoxitin, aztreonam,
imipenem and meropenem (Hotta et al., 2013). Velinov et al.
described 21 Bulgarian strains with a MIC range for ceftriaxone
between 2 and 4mg/L (Velinov et al., 2011). To date, two
β-lactamase genes (bla1 and bla2) have been identified in
the LVS strain (with corresponding homologs in the Schu S4
strain), but the expression of recombinant LVS proteins in
Escherichia coli only revealed the bla2LVS gene to encode a
functional β-lactamase (Bina et al., 2006). In 2012, Antunes
et al. reported a class A β-lactamase (FTU-1) present in 14
strains belonging to all F. tularensis subspecies, including various
type B strains from the USA, France, Japan, Russia, and
Sweden (Antunes et al., 2012). Actually, the FTU-1 corresponds
to the bla2LVS gene, as evidenced by comparison of gene
sequences (YP_513599.1 and FTT_0611c, respectively). This
class A β-lactamase, which was partially inactivated by β-
lactamase inhibitors, induced resistance to penicillin and a 4-
fold increase in ceftazidime MIC when cloned and expressed in
E. coli. This β-lactamase had no effect on other cephalosporins,
monobactams and carbapenems (Bina et al., 2006; Antunes et al.,
2012). The presence of the FTU-1/bla2LVS gene is thus compatible
with the cephalosporin-susceptibility phenotype observed in
Japanese strains, whereas additional resistance mechanisms
are probably involved in strains displaying resistance to
cephalosporins, monobactams and carbapenems (Table 5). In
2008, Bina et al. characterized an AcrAB RND eﬄux system
in the LVS strain, which conferred increased resistance to all
beta-lactams tested in the study (i.e., ampicillin, carbenicillin
and cefoperazone) but not to carbapenems (Bina et al., 2008).
Thus, β-lactams are not recommended for the treatment of
tularemia.
Chloramphenicol
The reported chloramphenicol MICs range from ≤ 0.023
to 4mg/L, with an MIC90 range of 0.25–2mg/L (Table 4).
Chloramphenicol has been used occasionally (alone or in
combination with other antibiotics) to treat patients with
tularaemia meningitis, owing to its high distribution in
brain tissue and cerebrospinal fluid (Tarnvik, 2007; Hofinger
et al., 2009). Considering the MIC breakpoint of 8mg/L, F.
tularensis can be considered susceptible to chloramphenicol,
but the clinical use of this antibiotic is currently restricted
to meningitis because of potential severe bone marrow
toxicity.
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Rifampicin
Rifampicin is active in vitro against F. tularensis but with
MICs ranging from ≤ 0.094 to 3mg/L, and a MIC90 range
of 0.25–1.5mg/L (Table 4). However, this antibiotic is not
recommended for tularaemia treatment because of potential
rapid selection of resistant mutants, as described by Johansson
et al. (2000) and Tarnvik (2007). It has been used in combination
with ciprofloxacin for treatment of an infected total knee
arthroplasty, with resolution of symptoms only after addition
of rifampicin and a successful outcome with this antibiotic
combination (Cooper et al., 1999).
New Antibiotics
Among more recently developed antibiotics, tigecycline, a new
glycylcycline, has been evaluated in two studies using the E-
test method, with reported MICs (0.094–0.38mg/L) and MIC90
(0.19–0.25mg/L) ranges lower than those determined in the same
studies for tetracycline and doxycycline (Tables 1, 4) (Yes¸ilyurt
et al., 2011; Kreizinger et al., 2013). No breakpoints are currently
defined for F. tularensis susceptibility to tigecycline, but all tested
strains displayed MICs ≤ 0.5mg/L. Further studies are needed
to evaluate tigecycline MICs using the microdilution reference
method. Importantly, fresh medium (< 24 h) must be used
to prevent overestimation of tigecycline MICs (Bradford et al.,
2005). Tigecycline might be a suitable alternative to doxycycline
for treatment of tularaemia, but its much broader antibacterial
spectrum is a disadvantage due to a greater deleterious effect on
the gut commensal flora.
Conflicting results were observed for linezolid, an
oxazolidinone compound. The activity of this antibiotic is
considered mainly restricted to Gram-positive bacteria, with
a CLSI susceptibility breakpoint for the corresponding species
set at ≤ 2mg/L. However, MICs of 4–8mg/L have been found
for Gram-negative bacteria of the genera Bacteroides, Moraxella
and Pasteurella, owing to the absence or low efficacy of eﬄux
systems, or a high affinity of their ribosomes for linezolid
(Livermore, 2003). As for F. tularensis, linezolid displayed MICs
of 0.5–2mg/L for 39 biovar II type B strains from Turkey,
2–4mg/L for eight type A strains from the USA, and 4–16mg/L
for 16 type B strains from the USA, when using the E-test strip
procedure. In contrast, MICs ranged from 12 to 48mg/L for 29
Hungarian biovar II type B strains using the same technique,
although such differences could be related to the use of different
solid media for AST (Tables 1, 4). The relative susceptibility of F.
tularensis to linezolid may be related to its small genome with a
limited number of eﬄux systems, while MIC variations between
strains may reflect variable expression of such eﬄux systems.
This hypothesis needs to be further assessed on a larger panel of
F. tularensis strains.
Conclusion
In conclusion, MIC data confirm that among the antibiotics
recommended as first-line treatment of tularaemia, ciprofloxacin
and levofloxacin display the lowest MIC ranges against F.
tularensis. Gentamicin ranks second, while doxycycline has the
highest MIC range with some strains displaying an MIC at
4mg/L, which is the breakpoint for susceptibility (4mg/L).
However, no resistant strains to any of these antibiotics have
been characterized so far. Moreover, chloramphenicol is active
and may be used in combination for rare meningitis due to
F. tularensis. Azithromycin and telithromycin may be useful
alternatives for infection related to biovar I strains of F.
tularensis subsp. holarctica, when all first line antibiotics are
contraindicated, but still require confirmation of their efficacy
in animal models. Tigecycline and rifampicin are active in
vitro and should be also further evaluated in animal models.
Rifampicin may be an interesting antibiotic in association to
fluoroquinolones for rare bone and joint infections.
MBCS AND OTHER BACTERICIDAL
ASSAYS
A few in vitro studies have reported either MBC or time-kill
kinetic experiments for F. tularensis. MBC testing is performed
similarly to MIC testing using a broth microdilution method,
but an aliquot of each well with no visible growth after 48 h
incubation is plated on enriched chocolate agar media for CFU
count determination. After 48 h incubation of the chocolate agar
plates at 37◦C, under 5% CO2 atmosphere, CFU counting can
determine the MBC, which is the lowest antibiotic concentration
allowing 3-log or greater reduction of the primary bacterial
inoculum.
Time-kill kinetic experiments determine CFU counts over
time in antibiotics containing cultures, incubated for 48 h at
37◦C, under 5% CO2 atmosphere. Experiments are conducted
using enriched caMHB medium, containing two, four or eight
times the MIC of the tested antibiotic compound (Maurin et al.,
2000; Caspar et al., 2014).
The MBCs of several antibiotics (ceftriaxone, streptomycin,
amikacin, gentamicin, thiamphenicol, telithromycin,
erythromycin, clarithromycin, rifampicin, ofloxacin,
ciprofloxacin, pefloxacin, doxycycline, and cotrimoxazole)
were determined against a single human strain of F. tularensis
subsp. holarctica biovar I, using the modified MHII as the
experimental medium (Maurin et al., 2000). MBCs were equal
to MICs for ofloxacin and ciprofloxacin; 2-fold higher for the
aminoglycosides (streptomycin, amikacin, and gentamicin),
thiamphenicol, telithromycin, rifampicin, pefloxacin, and
doxycycline; 4-fold higher for erythromycin; 16 times higher
for cotrimoxazole; and 32 times higher for clarithromycin.
Despite a MIC of 2mg/L, a bactericidal effect was never observed
with ceftriaxone against F. tularensis, although β-lactams are
classically considered bactericidal drugs against most other
bacteria susceptible to these compounds. The latter results
reinforce prior statements that β-lactams and cotrimoxazole are
not reliable for tularaemia treatment (Tarnvik, 2007). According
to this work, most antibiotics tested could be considered
as bactericidal against F. tularensis. However, it should be
mentioned that the use of modified MH2 in these experiments
may have influenced both the bacteriostatic and the bactericidal
activity of antibiotics compared to caMHB, as previously
discussed. Indeed, in that study, the MIC value for doxycycline
was 8 mg/L, which is higher than usually found in other studies.
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We recently evaluated MBCs for gentamicin and doxycycline
against the LVS strain and two human strains of F. tularensis
subsp. holarctica biovar I from France, using caMHB medium
(Caspar et al., 2014). The MBC was 8-fold higher than the MIC
for gentamicin (respectively, 2 and 0.25mg/L) and could not
be determined for doxycycline, which was mainly bacteriostatic
(MIC = 0.25mg/L) (Caspar et al., 2014). These data are more in
agreement with the known bactericidal and bacteriostatic nature
of these two antibiotics, respectively. Such a difference may
participate to the lower relapse rates reported with gentamicin
(Enderlin et al., 1994).
Finally, a third study measured the MBCs of ciprofloxacin,
gentamicin and doxycycline against the LVS strain, using
enriched caMHB medium (Aloni-Grinstein et al., 2015). The
MBC/MIC ratios were measured at 1–2 for gentamicin and ≤
4 for ciprofloxacin, confirming the bactericidal nature of these
antibiotics against F. tularensis. The MBC/MIC ratio was equal
to 4 for chloramphenicol. In contrast, the MBC/MIC ratio was
≥ 64 for doxycycline, demonstrating a bacteriostatic activity
(Aloni-Grinstein et al., 2015).
In conclusion, MBC data investigated with suitable media
for F. tularensis AST revealed a bactericidal activity for the
aminoglycosides and the fluoroquinolones, but a bacteriostatic
activity for doxycycline. These data should be further confirmed
using a larger sample of F. tularensis strains.
CELL SYSTEMS
The activity of antibiotics against F. tularensis has rarely
been evaluated in cell models. These models used either of
the following cell systems: murine macrophage-like cell lines
J774.1 or P388D1; kidney epithelial Vero cells from African
green monkey; human cell lines, including lung epithelial
A549 cells, pulmonary fibroblastic MRC5 cells, non-phagocytic
kidney epithelial HEK 293 and THP-1 human monocytes; or
human monocytes purified from buffy coat (Maurin et al., 2000;
Golovliov et al., 2003; Madrid et al., 2013; Schmitt et al., 2013;
Sutera et al., 2014). In these models, the multiplicity of infection
(MOI, bacteria/eukaryotic cell ratios used for cell infection)
varied between 10 and 3000 according to the F. tularensis
strain used (i.e., F. tularensis subsp. tularensis SchuS4 strain, F.
tularensis subsp. holarctica FSC200 strain, or LVS) and the nature
of the eukaryotic cells. Cell infection usually occurs after 2–3
h of bacteria–cell contact. The penetration of bacteria within
eukaryotic cells may be enhanced by centrifugation of infected
cell monolayers (Maurin et al., 2000; Madrid et al., 2013; Schmitt
et al., 2013; Sutera et al., 2014; Aloni-Grinstein et al., 2015). Then
non-phagocytised bacteria are removed by adding gentamicin
to the extracellular medium for 1–4 h, which is referred to as
the gentamicin protection assay. The cell monolayers are then
washed and incubated at 37◦C in 5% CO2 atmosphere, either
in drug-free medium (growth control) or in the presence of the
tested antibiotics. At various incubation times, cell monolayers
are washed and lysed with detergents, and CFU counts in cell
lysates are determined. Antibiotic activity is deduced from the
ratio of CFU counts in antibiotic-containing cultures compared
to the drug-free growth control.
Alternative methods for the evaluation of antibiotic activity
against intracellular F. tularensis have been proposed. A dye-
uptake assay based on the capacity of eukaryotic cells to
internalize a vital dye has recently been reported. In this model,
activity of antibiotics is deduced from their ability to inhibit
bacterial growth within eukaryotic cells, preventing lysis of the
cell monolayers. The term “minimal inhibitory extracellular
concentration” (MIEC) was coined to define the minimal
extracellular antibiotic concentration capable of preventing
cytotoxic effects of F. tularensis multiplication (Sutera et al.,
2014). The turnaround time of the dye uptake assay was 2
days compared to 4–5 days for the CFU count-based model.
Cell mortality could also be evaluated by measuring lactate
dehydrogenase activity in cell supernatants (Madrid et al., 2013).
More recently, a qPCR assay was used to determine F. tularensis
growth in Vero cells (Aloni-Grinstein et al., 2015). MIECs were
determined after 24 h infection, with results comparable to those
obtained with the CFU method (Aloni-Grinstein et al., 2015).
However, qPCR may overestimate viable bacterial loads since it
quantifies DNA from both viable and non-viable bacteria.
Fluoroquinolones
The intracellular activity of antibiotics against a French type B
biovar I strain of F. tularensis (erythromycin MIC of 4mg/L)
was evaluated in a P388D1 murine macrophage-like cell model,
using the CFU count methodology (Maurin et al., 2000). The
results showed that ciprofloxacin and ofloxacin at 1mg/L were
the most potent compounds, with more than a 4- and 3-
log reduction of bacterial inocula after only 48 h incubation
of cultures, respectively (Maurin et al., 2000). In a systematic
screening of FDA-approved drugs to identify compounds that
may inhibit multiplication of biological threat agents, including
F. tularensis, norfloxacin (50 µM, i.e., 16mg/L) exhibited 83%
protection of cells against cytotoxicity of the SchuS4 strain in
J774.1 murine macrophages, as determined by the supernatant’s
lactate dehydrogenase activity (Madrid et al., 2013). In a dye-
uptake assay using MRC5 cells, MIECs and MICs were equal
for ciprofloxacin, levofloxacin andmoxifloxacin, suggesting good
penetration of these antibiotics within F. tularensis-infected cells
(Sutera et al., 2014).
Tetracyclines
In the P388D1 murine macrophage-like model, doxycycline
at 4mg/L only induced a 2-log reduction of bacterial inocula
after 72 h incubation (Maurin et al., 2000). In the systematic
screening assay of FDA-approved drugs, tetracycline completely
protected infected cells from cytotoxicity of the SchuS4 strain
at 50 µM (22mg/L), and minocycline induced 92% survival
of infected cells at 23mg/L (Madrid et al., 2013). In the dye
uptake assay, MIECs were also equal to MIC for doxycycline, also
demonstrating good penetration within infected cells. However,
MIEC values were eight times higher for doxycycline (0.5mg/L)
compared to ciprofloxacin (0.064mg/L) against the two biovar
I type B strains evaluated in the study. In another study, the
same ciprofloxacin MIEC was found for the LVS strain in Vero
cells, as determined by both qPCR and CFU count methods,
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but a lower MIEC (0.125–0.5mg/L) was found for doxcycline
(Aloni-Grinstein et al., 2015).
Aminoglycosides
In the P388D1 murine macrophage-like cell model, gentamicin
at 3mg/L was not bactericidal after 48 h incubation of cultures
and only induced a 1-log reduction of the bacterial inoculum
after 72 h incubation. When tested at 10mg/L, a 2-log reduction
of bacterial counts was observed after 48 h incubation and more
than 3-log reduction after 72 h (Maurin et al., 2000). In another
study using the attenuated LVS strain and the Vero cell line,
gentamicin at 20mg/L did not show any intracellular activity
after 32 h incubation (Aloni-Grinstein et al., 2015). In the dye-
uptake assay using MRC5 cells, the gentamicin MIEC after 48 h
incubation of cultures was 2 mg/L against two French type B
biovar I strains of F. tularensis, while the MICs of this antibiotic
were, respectively, 0.25 and 0.5 mg/L for the same strains (Sutera
et al., 2014). Delayed activity of gentamicin correlated with the
slow penetration of this antibiotic within eukaryotic cells, usually
detectable only after 48–72 h of antibiotic–cell contact.
The other aminoglycosides also penetrate slowly within
eukaryotic cells. Amikacin and streptomycin, at 10 mg/L, only
decreased F. tularensis inoculum by 1 log after 48 h, and 2 logs
after 72 h (Maurin et al., 2000). In contrast, netilmicin did not
prevent cell lysis in J774.1 cells infected with the SchuS4 strain
(Madrid et al., 2013).
Macrolides/Lincosamides/Ketolides
Conflicting results have been reported between studies testing
the intracellular form of F. tularensis, which may be due to
the use of different cell types and bacterial strains. In P388D1
murine macrophage-like cells, erythromycin and clarithromycin
at 4 mg/L exhibited no intracellular activity against a type B
biovar I strain of F. tularensis displaying MICs of 4 and 8 mg/L
in acellular media for these antibiotics, respectively. In contrast,
telithromycin at 4 mg/L (MIC at 0.5 mg/L in acellular medium)
was able to reduce the bacterial inoculum between two to three
log10 after 72 h (Maurin et al., 2000). Unlike telithromycin, the
intracellular concentration of erythromycin and clarithromycin
was probably not sufficient in this experiment to kill bacteria, as
the extracellular concentration used was equal or superior to their
MIC. In another study, a high concentration of erythromycin
(50µM, 37 mg/L) conferred full protection of J774.1 cell viability
after infection with the SchuS4 type A strain (Madrid et al., 2013).
In the same assay, clindamycin (50µM, 21 mg/L) exhibited 83%
protection of cells against the cytotoxic effect of F. tularensis
proliferation (Madrid et al., 2013). In the dye uptake assay
reported by Sutera et al., erythromycin MIECs were four times
lower thanMICs (respectively, 1–2 mg/L and 4–16 mg/L) for two
French biovar I type B strains in MRC5 cells (Sutera et al., 2014).
Altogether, these experiments show that erythromycin may be
effective in preventing intracellular replication of type A and
biovar I type B strains.
In another experiment reported by Ahmad et al., azithromycin
(a C15 macrolide) showed complete killing of the LVS strain
at 5 mg/L in murine macrophage J774.1 cells, although this
antibiotic displays an MIC of 25 mg/L against this biovar II
type B strain (Ahmad et al., 2010). This result suggests a high
bactericidal concentration of azithromycin within F. tularensis-
infected J774.1 macrophages. This may not be true for all
cell types since a previous experiment from Ahmad et al.,
demonstrated that azithromycin was fully bactericidal at only 25
mg/L against the LVS strain grown in human lung epithelial A549
cells (Ahmad et al., 2010).
Beta-Lactams
In the P388D1 murine macrophage-like model, β-lactams
at 10 mg/L (penicillin G, amoxicillin, ceftriaxone) displayed
no activity against intracellular F. tularensis (Maurin et al.,
2000). Meropenem was ineffective against both intracellular and
extracellular F. tularensis in the dye uptake assay (Sutera et al.,
2014).
Other Antibiotics
In the P388D1 murine macrophage-like model, thiamphenicol at
4 mg/L displayed no intracellular activity. In contrast, rifampicin
at 4 mg/L induced a 2-log reduction of bacterial inocula after
72 h incubation (Maurin et al., 2000). In the dye uptake assay
using MRC5 cells, MIECs were close to MICs for rifampicin,
also suggesting good penetration of this compound within
F. tularensis-infected cells. However, MIEC values were 16
times higher than those of ciprofloxacin (1 vs. 0.064 mg/L,
respectively) against the two biovar I type B strains tested
for F. tularensis (Sutera et al., 2014). Interestingly, linezolid
exhibited higher activity against intracellular than extracellular
F. tularensis, suggesting its accumulation within MRC5 cells,
with a MIEC of 1 mg/L and an MIC of 8 mg/L (Sutera et al.,
2014). Finally, daptomycin was ineffective both intracellularly
and extracellularly (Sutera et al., 2014).
Conclusion of Intracellular Activity of
Antibiotics against Tularaemia
To summarize the data from the intracellular models, the
fluoroquinolones ciprofloxacin, levofloxacin, moxifloxacin and
ofloxacin displayed the lowest MIECs and the fastest bactericidal
activity against intracellular F. tularensis, suggesting rapid and
efficient concentration of these compounds within infected
eukaryotic cells. The tetracyclines were less effective and
mainly bacteriostatic against intracellular F. tularensis. The
aminoglycosides displayed a bactericidal activity, but only
after 48–72 h of antibiotic exposure of infected cells, which
correlated with the slow intracellular accumulation of these
basic compounds (Maurin and Raoult, 2001). Thus, the
aminoglycosides are probably much more effective against
the extracellular form of F. tularensis at the early stage of
antibiotic treatment, while these antibiotics may also be active
against intracellular F. tularensis after several days of treatment.
Streptomycin and amikacin were slightly less effective than
gentamicin at the same concentration, and netilmicin was
ineffective. The beta-lactams and daptomycin were not effective
in cell systems. In contrast, the activity of linezolid against
intracellular F. tularensis should be further investigated both
in vitro and in vivo.
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Interestingly, in two studies, the macrolides erythromycin and
azithromycin were found to be active against the intracellular
form of type A and biovar I type B F. tularensis strains, which
are naturally susceptible to these antibiotics. Azithromycin was
also effective against the intracellular form of biovar II type
B LVS strain, although naturally more resistant to macrolides,
but only in phagocytic and fibroblastic cells. Indeed, the
intracellular accumulation of the macrolides varies according to
the eukaryotic cell type considered, with a lower accumulation
in epithelial cells compared to phagocytic and fibroblast cells
(Ahmad et al., 2010; Sutera et al., 2014). PK/PD studies have
demonstrated the accumulation of azithromycin within human
phagocytic and fibroblast cells, and in many human tissues, such
as lungs, soft tissues, prostate and tonsils (McDonald and Pruul,
1991; Matzneller et al., 2013). The intracellular/extracellular
azithromycin ratio in tissues is generally between 10 and 100,
and can be >200 in polymorphonuclear (PMN) leukocytes, with
probable large amounts of this antibiotic at the site of infection
(Hand and Hand, 2001; Hall et al., 2002; Matzneller et al.,
2013). The intracellular accumulation of erythromycin is lower,
with intracellular/extracellular ratios generally between 1 and 10
in tissues and PMNs (McDonald and Pruul, 1991; Hand and
Hand, 2001). The activity of azithromycin against intracellular
F. tularensis warrants further evaluation of its activity in animal
models. These experiments should be conducted using type A
and type B strains, especially the type B biovar II strains.
ANIMAL MODELS
Although several animal models have been developed to study
the pathogenesis of F. tularensis infection and vaccine efficacy,
few of these models have evaluated in vivo antibiotic efficacy
(Rick Lyons and Wu, 2007). This may be related to the absence
of an optimal animal model mimicking human infection. In
these models, antibiotic activity is usually deduced from the
death rate and survival time of infected animals and the bacterial
load in their organs (especially in the spleen) at the time of
death or sacrifice, when treated with various antibiotic regimens
compared to infected and untreated controls. BALB/c and
C57BL/6 mice and guinea pigs are highly susceptible hosts to
F. tularensis infection, but also to the LVS strain of F. tularensis
subsp. holarctica and F. novicida strains, which have often been
used as surrogates of F. tularensis, although they are much less
virulent in humans (Stundick et al., 2013; Kingry and Petersen,
2014). Rabbits and Fisher 344 rats are less susceptible to F.
tularensis infection and may better mimic human infection.
However, variable immune responses to F. tularensis infection
also exist between rat strains, with Sprague-Dawley being much
more resistant than Fisher 344 rats (Raymond and Conlan,
2009). Results may also vary according to the route of infection,
i.e., the intraperitoneal, intradermal, subcutaneous or intranasal
routes for Fischer 344 rats (Stundick et al., 2013). Moreover, the
“Animal Rule” states that experimental animal models should be
developed using the true etiologic agent causing human disease.
Thus, evaluation of antibiotic activity in Fisher 344 rats infected
with virulent type A or type B strains would be more predictive
of the clinical situation.
Few experiments have evaluated the activity of antibiotics in
F. tularensis-infected animal models. However, interesting
data have been obtained regarding the in vivo efficacy
of antibiotics, and relapse rates according to delay in
antibiotic therapy and treatment duration. Unfortunately,
these models are highly heterogeneous with respect to the
route of infection, the route of antibiotic administration,
the antibiotic dose administrated and the F. tularensis strain
tested.
Fluoroquinolones and Doxycycline
In 1998, Russel et al evaluated the effect of subcutaneous
injection of doxycycline or ciprofloxacin on the median lethal
dose (MLD) of the Schu S4 strain injected intraperitoneally
to Porton outbred mice (Russell et al., 1998). The animals
either received a 2-day antibiotic prophylaxis before the bacterial
challenge, or were treated 48 h post-infection with 20 or 40
mg/kg twice a day, of doxycycline or ciprofloxacin for 10 days,
and then were monitored for 24 days. Although the MLD was
close to 1 CFU of the Schu S4 strain in untreated mice, full
protection at the highest bacterial inoculum tested (8.8 × 106
CFU) was achieved by a 2-day prophylaxis with ciprofloxacin
or doxycycline, and by 10 days of post-infection treatment with
either of these antibiotics at 40 mg/kg twice a day. At this dosage,
the serum concentrations were higher than 4 × MIC for at least
12 h for ciprofloxacin, and 3 × MIC for 9 h for doxycycline
(Russell et al., 1998).
The in vivo efficacy of fluoroquinolones was confirmed
in 2005, by Piercy et al. (2005). BALB/c mice were infected
subcutaneously with 106 CFU of the Schu S4 strain and
treated orally with 100 mg/kg of ciprofloxacin, gatifloxacin or
moxifloxacin, from 6 h to 14 days post-infection. Survival rates
at day 42 post-infection were 94, 100, and 100%, respectively, for
these three antibiotics (Piercy et al., 2005).
In 2008, Klimpel et al. showed that a 13-day course
of levofloxacin (5mg/kg/day, intraperitoneally), starting
24 h following an intranasal challenge with 3 LD50 of
F. tularensis Schu S4 strain, prevented death of all Balb/c
mice (Klimpel et al., 2008). No bacteria were detectable
in the spleen of the animals after 10 days of treatment,
while very few were detected in the lungs at this time
(Klimpel et al., 2008).
In 2012, Rotem et al. compared the efficacy of ciprofloxacin
and doxycycline in Balb/c mice infected by inhalation of a 100-
LD50 dose of F. tularensis LVS (105 CFU) or Schu S4 (102
CFU) strains (Rotem et al., 2012). Untreated controls died 5–7
days post-infection, whereas all LVS-infected mice were cured
by intraperitoneal injection of ciprofloxacin (50 mg/kg bid) for
7 days or doxycycline (40 mg/kg bid) for 14 days, whether the
antibiotic treatment was started at 24, 48, or 72 h post-infection
(Rotem et al., 2012). F. tularensis LVS strain was undetectable
by culture in the lungs, liver and spleen after completion of
any of these treatments. In contrast, for animals infected with
the Schu S4 strain, no death occurred when ciprofloxacin was
administered 24 or 48 h post infection, while doxycycline only
cured 90% of the animals even when administrated 24 h post-
infection (Rotem et al., 2012).
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Treatment Delay
In the study from Russel et al., a 48-h prophylaxis with
ciprofloxacin or doxycycline protected mice from a 3.7 × 106
CFU and 6.0 × 106 CFU challenge with the Schu S4 strain,
respectively (Russell et al., 1998). In contrast, when antibiotic
treatment was started 24 h post-infection, complete protection
was only obtained against an intraperitoneal challenge with 880
CFU for ciprofloxacin and 100 CFU for doxycycline. Thus,
antibiotic efficacy was dramatically reduced after only 24 h
infection (Russell et al., 1998). In the study by Rotem et al.,
in which mice were infected via Schu S4 strain aerosols, no
death occurred when ciprofloxacin was administered 24–48 h
post infection, while a 30% mortality rate was observed when
this antibiotic was administered 3 days post-infection (Rotem
et al., 2012). Doxycycline only cured 90, 30, and 0% of the
mice when started at 24, 48, and 72 h post-infection, respectively
(Rotem et al., 2012). In the study reported by Piercy et al., the
survival rates decreased dramatically (94, 67, and 0%) when
ciprofloxacin was administrated 6, 24, or 48 h post-infection,
respectively (Piercy et al., 2005). In contrast, the survival rates
were 100, 96, and 84% for gatifloxacin, and 100, 100, and 62%
for moxifloxacin, respectively, showing the better therapeutic
efficacy of these drugs compared to ciprofloxacin. In this study,
the infectious dose wasmuch higher than in that fromRotem et al
(106 CFU intraperitoneally vs. 102 CFU intranasally). Finally, in
the Klimpel et al. study, full protection against the SchuS4 strain
(99 CFU intraperitoneally) was observed for levofloxacin at 40
mg/kg/day, as long as the treatment delay did not exceed 72 h
(Klimpel et al., 2008). If started at 72 h, bacterial load decreased
approximately from 106 to 10 CFU per organ after 1 week of
treatment. Delaying the treatment of more than 120 h resulted
in the death of all infected mice (Klimpel et al., 2008).
Bactericidal Activity and Treatment
Duration
In the Russel et al. study, when treatment was administrated for 5
days rather than 10 days post-infection, the MLD was reduced
from > 8.8 × 106 CFU to 3.7 × 106 CFU for ciprofloxacin
and 6.0 × 106 CFU for doxycycline (Russell et al., 1998). The
protective effect of the antibiotic therapy also decreased when
animals were treated with a lower dose (20 mg/kg bd rather
than 40 mg/kg bd) of ciprofloxacin or doxycycline. Moreover,
the authors reported that death occurred in 90% of animals
after antibiotic treatment withdrawal, demonstrating that a 5-day
course of antibiotic treatment was not sufficient to eradicate F.
tularensis (Russell et al., 1998). Thus, in this study, the dose and
length of the antibiotic therapy administered highly influenced
the outcome of F. tularensis infection in animals (Russell et al.,
1998).
Significant insight into relapses came from the study reported
by Piercy et al. (2005). Among the nine groups tested
(ciprofloxacin, moxifloxacin or gatifloxacin, initiated 6, 24, or 48
h post-infection), these authors showed that the administration
of 7 days of dexamethasone to surviving mice in order to abolish
their immune system resulted in 17–73% relapse rates depending
on the treatment group. These findings suggested that quiescent
bacteria controlled by the immune system persisted in mice
despite 14 days of fluoroquinolone therapy. Fluoroquinolones
were thus not fully bactericidal when a high inoculum of F.
tularensis was injected to the mice (e.g., subcutaneous injection
of 106 CFU of the Schu S4 strain). Suppression of the immune
system enabled latent bacteria to multiply and kill mice, even in
the 6-h post-exposure treatment group (respectively, 36 and 42%
mortality rates in the ciprofloxacin- and moxifloxacin-treated
groups; Piercy et al., 2005).
Data from the study by Rotem et al. corroborated this
hypothesis (Rotem et al., 2012). In their experiments with the
virulent Schu S4 strain, no death occurred when ciprofloxacin
was administered 24 or 48 h post-infection, while a 30%mortality
rate was observed when this antibiotic was administered 3 days
post-infection. In the latter case, bacteria were undetectable in
organs at the time of antibiotic treatment withdrawal, while
cultures were positive 3 days later for three out of 10 mice that
died after antibiotic withdrawal. The extension of ciprofloxacin
treatment duration from 7 to 10 days cured all animals, even
when the antibiotic was administrated 72 h post-infection. In
contrast, when doxycycline was started 72 h post-infection, all
animals had approximately 100 CFU/g of tissue (lungs, liver
or spleen) at the end of treatment, after which the bacterial
loads in organs increased in all mice until death. Extension of
treatment from 14 to 21 days resulted in no cultivable bacteria
in lungs, liver or spleen at the end of treatment, but all mice
relapsed after 2 days of doxycycline withdrawal (Rotem et al.,
2012). A different picture was observed with the LVS strain,
which was below detectable level by culture in the lungs, liver
and spleen after completion of any of the treatment regimens
(ciprofloxacin for 7 days or doxycycline for 14 days, started 24,
48, and 72 h post-infection) in the mice sacrificed at the end
of the treatment. However, 2 days after doxycycline treatment
withdrawal, the LVS strain was detected in all organs, and
bacterial loads gradually decreased to an undetectable level in
the following 7 days and resulted in no death. Thus, although
undetectable after doxycycline treatment, the attenuated LVS
strain was not fully eradicated and regrowth of the bacteria was
observed as soon as doxycycline was stopped, although it did
not kill the mice. In contrast, re-emergence of bacteria did not
occur for the ciprofloxacin group of LVS-infected mice after
ciprofloxacin withdrawal.
Conclusions Drawn from Animal Model
Data
Altogether, these data indicate that both ciprofloxacin and
doxycycline are able to prevent tularaemia in mice when
treatment is started 48 h before a challenge with F. tularensis
SchuS4 strain. These antibiotics are also able to cure the disease
and eradicate F. tularensis when administrated post-infection at
a concentration of 40 mg/kg or higher, for 5–10 days. Efficacy of
the antibiotic treatment is highly correlated with the antibiotic
dose administered, which is probably related to the duration over
which serum concentrations of antibiotics are above the MIC
values of the infecting strain.
However, when treatment was started 24–72 h post-infection,
ciprofloxacin was superior to doxycycline: (1) in the study
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conducted by Rotem et al., doxycycline was not able to cure all
mice when infected with 102 CFU of the SchuS4 strain via the
aerosol route, even when started at 24 h post-infection, while
ciprofloxacin cured all mice when started either 24 or 48 h post-
infection (Rotem et al., 2012); (2) relapse rates were higher for
doxycycline as it was unable to fully eradicate the Schu S4 or LVS
strains from the lungs, liver and spleen, even when administrated
for 14–21 days; (3) the time until antibiotic treatment initiation
reduced doxycycline efficacy much more than for ciprofloxacin.
F. tularensis multiplies within the slightly acidic cytosol
of eukaryotic cells, and a low pH may alter the activity
of the basophilic antibiotics ciprofloxacin and doxycycline
(Russell et al., 1998). Data obtained in animal models indicate
that persistent bacteria may develop in hosts infected with
F. tularensis when the antibiotic therapy administered has
poor bactericidal activity or is too short in duration. These
data suggest that long antibiotic treatment duration should
be used in immunocompromised patients infected with F.
tularensis. This could also be true for patients suffering from
suppurated lymphadenopathy, who often experience relapses
despite administration of ciprofloxacin for 14 days or doxycycline
for 21 days.
Treatment must be initiated as soon as possible since
antibiotic efficacy decreased significantly when treatment was
delayed by 24–48 h post-infection. It should be noted that,
because of diagnosis delays, antibiotics are often given several
days to weeks after infection in patients suffering from
tularaemia. Importantly, moxifloxacin efficacy was less impacted
by treatment delay than ciprofloxacin and thus may represent an
advantageous therapeutic option in case of late diagnosis. MIC
values are close for moxifloxacin and ciprofloxacin.
GENERAL CONCLUSION AND
PERSPECTIVES
Since the introduction of streptomycin in the mid-1950s,
antibiotic treatment of human tularaemia has remained
challenging. In most tularaemia endemic countries, human
infections are now rare, and F. tularensis isolation is even
rarer. Thus, AST data for isolated strains of F. tularensis may
not reflect the true situation of current antibiotic resistance in
this pathogen. Importantly, the analysis of AST methodological
variations between studies shows an urgent need for international
standardization. Following the CLSI guidelines, including using
the appropriate experimental medium, bacterial inoculum and
incubation time are mandatory, although some F. tularensis
strains grow better or exclusively under 5%CO2 atmosphere. The
broth microdilution technique using enriched caMHB medium
should be considered the reference method. As recommended
by the CLSI, a final inoculum calibrated at 5 105 CFU/mL should
be used, as a 10-fold higher or lower inoculum is associated to
interpretation errors (Georgi et al., 2012). However, the modified
Mueller-Hinton II liquid medium should not be used for F.
tularensis AST to avoid reporting MICs that could categorize F.
tularensis strains as resistant to aminoglycosides or doxycycline
whereas such resistances have never been characterized so far in
this pathogen. From the data currently available, use of the CLSI
broth microdilution method can be recommended to test large
collections of F. tularensis strains in reference laboratories, while
the E-test method would be more convenient for testing one or
a few strains. However, the E-test MIC strip method, although
more convenient to perform, still requires comparative studies
with the reference method.
Altogether, available AST data indicate that the
fluoroquinolones display the lowest MICs, are strongly and
rapidly bactericidal in cell models and are highly effective in
curing F. tularensis infection in infected mice when administered
for at least 10 days. Among the fluoroquinolones, ciprofloxacin
and levofloxacin have the lowest MICs. In contrast, doxycycline
MICs are closer to the CLSI susceptibility breakpoint and this
antibiotic is only bacteriostatic in cell models. In the mouse
model, a 14-day course of doxycycline did not eradicate F.
tularensis when treatment was started 72 h post-infection
(Rotem et al., 2012). A 21-day course of treatment was still
not fully effective to eradicate bacteria, whereas 10 days of
ciprofloxacin treatment was effective. Therefore, doxycycline
should be considered less effective than fluoroquinolones
for treatment of tularaemia, which is consistent with higher
therapeutic failure rates in humans observed with this antibiotic.
Because antibiotic treatment is often administrated several days
after symptom onset in tularaemia patients, ciprofloxacin may be
a better choice than doxycycline. Moreover, treatment duration
with ciprofloxacin of at least 14 days should be recommended,
while 3 weeks would be a minimum for doxycycline (Rotem
et al., 2012). A longer duration of antibiotic treatment should
probably be considered in case treatment is delayed longer
than 2 weeks after symptom onset, especially if lymph node
suppuration or other local or systemic complications have
occurred. The aminoglycosides (especially gentamicin) also
have low MICs. They are rapidly bactericidal in acellular media,
but their intracellular bactericidal activity only takes place after
72 h of cell exposure owing to their slow penetration through
the eukaryotic cell membrane. In the 1994 review by Enderlin
et al., streptomycin was considered the most reliable treatment
for human tularaemia, with almost no relapse after treatment
removal (Enderlin et al., 1994). The aminoglycosides are still
considered the most reliable treatment of severe tularaemia cases
(e.g., the pneumonic and typhoidal forms of tularaemia, and all
other systemic infections). Experimental data suggest that the
combination of an aminoglycoside with a fluoroquinolone may
currently be the most effective alternative in patients with severe
tularaemia, especially to obtain a rapid bactericidal activity
against extracellular and intracellular F. tularensis. However, one
has always to remember that antimicrobial potency deduced
from MIC values, MBC values, in vitro and in vivo bactericidal
activity in animal models is only one of many factors (including
pharmacokinetic and pharmacodynamic parameters, tolerability,
plasma protein binding, tissue penetration, bactericidal activity,
and contraindication) that may influence the decision of what
drug to use in a clinical setting.
The macrolides (especially azithromycin) could be an
alternative in patients infected with erythromycin-susceptible
strains of F. tularensis (type A and type B biovar I) and in those
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for whom the above first-line treatments are contraindicated,
including young children and pregnant women. However, the
macrolide-resistant type B biovar II strains are currently found
in Eastern Europe and in Asia, and co-exist with biovar I strains
in Germany, Switzerland and Scandinavia. The empirical use of
a macrolide in tularaemia patients cannot be considered reliable
in these areas. The use of a macrolide in patients with mild to
moderate severity tularaemia is safer in Western Europe, where
only type B biovar I strains cause human infections. In this
context, quick discrimination between type B biovar I and II
strains either by determination of erythromycin susceptibility
(using MIC strips or sequencing of rrl gene) or by detection
of particular genetic markers (detection of RD23 deletion only
found in West European strains) would be of particular interest
(Dempsey et al., 2007; Pilo et al., 2009; Karlsson et al., 2016).
Since these antibiotics mainly display a bacteriostatic activity
against F. tularensis, they cannot be considered reliable to treat
severe forms of tularaemia. Azithromycin combined with lymph
node resection proved to be effective to cure a pregnant women
suffering from oropharyngeal tularaemia with no complications
for the fetus (Dentan et al., 2013). Further in vivo data in
animal models and humans are needed before azithromycin
can be recommended as a reliable alternative for treatment of
tularaemia.
Finally, the causes of the high relapse rates observed in
tularaemia patients after administration of a fluoroquinolone or
a tetracycline remain undetermined. Several hypotheses can be
proposed, including low penetration of antibiotics in tissues and
eukaryotic cells in vivo; low susceptibility of bacteria in vivo
especially because of low replication and persistence; inactivation
of antibiotic activity in vivo owing to local conditions (e.g.,
acidic pH, enzymatic inactivation, etc.) and acquired resistance
to antibiotics in vivo in patients under fluoroquinolone or
tetracycline treatment. Further evaluation of such hypotheses in
in vitro and in vivo experimental models is warranted.
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